Outlook Therapeutics, Inc.
OTLK · NASDAQ
9/30/2025 | 9/30/2024 | 9/30/2023 | 9/30/2022 | |
|---|---|---|---|---|
| Market Cap | $36,884 | $99,052 | $55,285 | $258,738 |
| - Cash | $8,083,085,000 | $14,928 | $23,392 | $17,397 |
| + Debt | $247,698,000 | $29,738 | $35,555 | $10,958 |
| Enterprise Value | -$7,835,350,116 | $113,862 | $67,449 | $252,299 |
| Revenue | $1,413,535,000 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $57,205,000 | -$114 | -$44 | -$205 |
| % Margin | 4% | – | – | – |
| EBITDA | -$67,061,666,000 | -$72,093 | -$57,376 | -$64,357 |
| % Margin | -4,744.3% | – | – | – |
| Net Income | -$62,424,863,000 | -$75,367 | -$58,983 | -$66,052 |
| % Margin | -4,416.2% | – | – | – |
| EPS Diluted | -1.79 | -4.06 | -4.72 | -6.23 |
| % Growth | 55.9% | 14% | 24.2% | – |
| Operating Cash Flow | -$51,829,437,000 | -$68,794 | -$42,973 | -$56,675 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$51,829,437,000 | -$68,794 | -$42,973 | -$56,675 |